Pamexin in the development of olinvesimab, a new drug for lung cancer

Founded in 2008, a research-oriented antibody therapy development company, listed on the KOSDAQ market as a technology exception in 2018. Research and development of new biopharmaceuticals and profits are generated through technology transfer.

It possesses core technologies such as complete human antibody development technology using phage library, original technology for manufacturing next-generation dual target antibodies, and antibody manufacturing technology using cancer stem cell library.

The main pipeline is tanivirumab, which is an antibody therapy that inhibits tumor growth and metastasis by inhibiting tumor angiogenesis.

2020/08/12 - [KOSDAQ] - Seoul Viosys boasting COVID-19 sterilization UV LED technology

2020/08/08 - [KOSPI] - Samsung C&T floating in Banpo Jugong 1st Complex

2020/08/03 - [KOSPI] - Samsung Biologics' share price surges with corona treatment contract